Research programme - microbiome therapeutics - Seres Therapeutics/Memorial Sloan Kettering Cancer Center

Drug Profile

Research programme - microbiome therapeutics - Seres Therapeutics/Memorial Sloan Kettering Cancer Center

Latest Information Update: 23 May 2016

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; Seres Therapeutics
  • Class Bacteria
  • Mechanism of Action Bacteria replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Graft-versus-host disease

Most Recent Events

  • 12 May 2016 Microbiome therapeuticsTM platform licensed to Seres therapeutics worldwide
  • 12 May 2016 Preclinical research in Cancer in USA (unspecified route)
  • 12 May 2016 Seres Therapeutics has global patent protection for the use of bacterial compositions in treatment of haematopoietic stem cell transplant patients
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top